Who enrolls in the medicare part D prescription drug benefit program? Medication use among patients with heart failure

Zubin J. Eapen, Bradley G. Hammill, Soko Setoguchi Iwata, Kevin A. Schulman, Eric D. Peterson, Adrian F. Hernandez, Lesley H. Curtis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background--Dispensing data from Medicare Part D standalone prescription drug plans are now available, but characteristics of enrollees with heart failure have not been well described. Methods and Results--We identified 81 874 patients with prevalent heart failure as of January 1, 2010, in a nationally representative 5% sample of Medicare beneficiaries. We classified patients according to enrollment in a Medicare Part D plan as of January 1, 2010. Demographic characteristics, comorbid conditions, and prescriptions were compared by enrollment status. A total of 49 252 (60.2%) were enrolled in a Medicare Part D plan as of January 1. Enrollees were more often women, black, and of lower socioeconomic status. Enrollees with heart failure more often filled prescriptions for loop diuretics than angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, or aldosterone antagonists. During the first 4 months of 2010, 5444 (12.3%) reached the coverage gap, and 566 (1.3%) required catastrophic coverage beyond the gap. Conclusions--Medicare beneficiaries with heart failure differ significantly according to enrollment in Part D prescription drug plans and represent a population underrepresented in clinical efficacy trials. Many face the coverage gap, and few select Medicare Part D plans that provide coverage during the gap. Linking Medicare Part D event data with clinical registries could help to determine whether eligible enrollees are undertreated for heart failure.

Original languageEnglish (US)
Article numbere000242
JournalJournal of the American Heart Association
Volume2
Issue number5
DOIs
StatePublished - Jan 1 2013

Fingerprint

Medicare Part D
Prescription Drugs
Heart Failure
Medicare
Prescriptions
Mineralocorticoid Receptor Antagonists
Sodium Potassium Chloride Symporter Inhibitors
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Social Class
Registries
Demography
Clinical Trials
Population

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Keywords

  • Heart failure
  • Medicare Part D
  • Outcome assessment (health care)

Cite this

Eapen, Zubin J. ; Hammill, Bradley G. ; Setoguchi Iwata, Soko ; Schulman, Kevin A. ; Peterson, Eric D. ; Hernandez, Adrian F. ; Curtis, Lesley H. / Who enrolls in the medicare part D prescription drug benefit program? Medication use among patients with heart failure. In: Journal of the American Heart Association. 2013 ; Vol. 2, No. 5.
@article{f0698f57cc784fe98beba26b0d050035,
title = "Who enrolls in the medicare part D prescription drug benefit program? Medication use among patients with heart failure",
abstract = "Background--Dispensing data from Medicare Part D standalone prescription drug plans are now available, but characteristics of enrollees with heart failure have not been well described. Methods and Results--We identified 81 874 patients with prevalent heart failure as of January 1, 2010, in a nationally representative 5{\%} sample of Medicare beneficiaries. We classified patients according to enrollment in a Medicare Part D plan as of January 1, 2010. Demographic characteristics, comorbid conditions, and prescriptions were compared by enrollment status. A total of 49 252 (60.2{\%}) were enrolled in a Medicare Part D plan as of January 1. Enrollees were more often women, black, and of lower socioeconomic status. Enrollees with heart failure more often filled prescriptions for loop diuretics than angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, or aldosterone antagonists. During the first 4 months of 2010, 5444 (12.3{\%}) reached the coverage gap, and 566 (1.3{\%}) required catastrophic coverage beyond the gap. Conclusions--Medicare beneficiaries with heart failure differ significantly according to enrollment in Part D prescription drug plans and represent a population underrepresented in clinical efficacy trials. Many face the coverage gap, and few select Medicare Part D plans that provide coverage during the gap. Linking Medicare Part D event data with clinical registries could help to determine whether eligible enrollees are undertreated for heart failure.",
keywords = "Heart failure, Medicare Part D, Outcome assessment (health care)",
author = "Eapen, {Zubin J.} and Hammill, {Bradley G.} and {Setoguchi Iwata}, Soko and Schulman, {Kevin A.} and Peterson, {Eric D.} and Hernandez, {Adrian F.} and Curtis, {Lesley H.}",
year = "2013",
month = "1",
day = "1",
doi = "https://doi.org/10.1161/JAHA.113.000242",
language = "English (US)",
volume = "2",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "5",

}

Who enrolls in the medicare part D prescription drug benefit program? Medication use among patients with heart failure. / Eapen, Zubin J.; Hammill, Bradley G.; Setoguchi Iwata, Soko; Schulman, Kevin A.; Peterson, Eric D.; Hernandez, Adrian F.; Curtis, Lesley H.

In: Journal of the American Heart Association, Vol. 2, No. 5, e000242, 01.01.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Who enrolls in the medicare part D prescription drug benefit program? Medication use among patients with heart failure

AU - Eapen, Zubin J.

AU - Hammill, Bradley G.

AU - Setoguchi Iwata, Soko

AU - Schulman, Kevin A.

AU - Peterson, Eric D.

AU - Hernandez, Adrian F.

AU - Curtis, Lesley H.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background--Dispensing data from Medicare Part D standalone prescription drug plans are now available, but characteristics of enrollees with heart failure have not been well described. Methods and Results--We identified 81 874 patients with prevalent heart failure as of January 1, 2010, in a nationally representative 5% sample of Medicare beneficiaries. We classified patients according to enrollment in a Medicare Part D plan as of January 1, 2010. Demographic characteristics, comorbid conditions, and prescriptions were compared by enrollment status. A total of 49 252 (60.2%) were enrolled in a Medicare Part D plan as of January 1. Enrollees were more often women, black, and of lower socioeconomic status. Enrollees with heart failure more often filled prescriptions for loop diuretics than angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, or aldosterone antagonists. During the first 4 months of 2010, 5444 (12.3%) reached the coverage gap, and 566 (1.3%) required catastrophic coverage beyond the gap. Conclusions--Medicare beneficiaries with heart failure differ significantly according to enrollment in Part D prescription drug plans and represent a population underrepresented in clinical efficacy trials. Many face the coverage gap, and few select Medicare Part D plans that provide coverage during the gap. Linking Medicare Part D event data with clinical registries could help to determine whether eligible enrollees are undertreated for heart failure.

AB - Background--Dispensing data from Medicare Part D standalone prescription drug plans are now available, but characteristics of enrollees with heart failure have not been well described. Methods and Results--We identified 81 874 patients with prevalent heart failure as of January 1, 2010, in a nationally representative 5% sample of Medicare beneficiaries. We classified patients according to enrollment in a Medicare Part D plan as of January 1, 2010. Demographic characteristics, comorbid conditions, and prescriptions were compared by enrollment status. A total of 49 252 (60.2%) were enrolled in a Medicare Part D plan as of January 1. Enrollees were more often women, black, and of lower socioeconomic status. Enrollees with heart failure more often filled prescriptions for loop diuretics than angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, or aldosterone antagonists. During the first 4 months of 2010, 5444 (12.3%) reached the coverage gap, and 566 (1.3%) required catastrophic coverage beyond the gap. Conclusions--Medicare beneficiaries with heart failure differ significantly according to enrollment in Part D prescription drug plans and represent a population underrepresented in clinical efficacy trials. Many face the coverage gap, and few select Medicare Part D plans that provide coverage during the gap. Linking Medicare Part D event data with clinical registries could help to determine whether eligible enrollees are undertreated for heart failure.

KW - Heart failure

KW - Medicare Part D

KW - Outcome assessment (health care)

UR - http://www.scopus.com/inward/record.url?scp=84891684757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891684757&partnerID=8YFLogxK

U2 - https://doi.org/10.1161/JAHA.113.000242

DO - https://doi.org/10.1161/JAHA.113.000242

M3 - Article

VL - 2

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 5

M1 - e000242

ER -